Ligand-independent constitutive activation of Hh pathway in cancers is characterized by somatic mutations in Ptch1, Smo, or Sufu, consequently increasing Hh pathway activity and leading to a higher incidence of basal cellular carcinoma (BCC) and medulloblastoma. Here, SMO is linked to cancer.